Although cell therapies have shown great potential to treat life-threatening conditions such as cancer, they have yet to realize widespread adoption, due to some critical roadblocks, including financial and environmental costs.
The development process of cell therapies is extensive and requires a unique combination of expensive reagents and consumables, equipment, and experience to safely deliver a living drug to patients. Cell culture media and buffers customized and optimized to the growth characteristics of a specific cell type can positively impact critical aspects of development such as transduction efficiency, population doubling, yield, and maintenance of relevant phenotypes. This can greatly increase the therapeutic potency and expedite processes to accelerate time to market while reducing costs.
If custom media and buffers can streamline development significantly, why doesn’t everyone use custom designed media and buffers? Iterating media and reagents can be a time-consuming and costly process considering the amount of time needed for researching and sourcing components, and money spent on shipping, storage, quality control, validation of components, and waste from single-use plastics and minimal order volumes. Current scientific findings related to our environment paired with recent regulations and initiatives are telling. Future therapies and processes must ensure responsible environmental stewardship in addition to advanced curative potential. Nucleus Biologics and Stoic Bio’s ecosystem, including the award-winning NB-AIR™ and Krakatoa™, can simplify the process, reduce cost, and facilitate sustainable science.
In this webinar, joined by collaborators from the University of Pennsylvania and the Center for Breakthrough Medicines, we will cover how high quality GMP products such as custom media and buffers can improve processes, optimize critical quality attributes, and change the paradigm of cell culture science from research and development to bioreactor scale production.